Business Context and Reporting Period
Merit Medical Systems, Inc. (MMSI) filed a Form 8-K on April 13, 2026. The filing provides historical revenue information disaggregated by new "Foundational" and "Therapeutic" product categories for the years ended December 31, 2022 through 2025, and quarterly data for 2024 and 2025. The company states this data is for period-over-period comparison purposes and does not constitute a revision or restatement of previously reported consolidated financial statements.
Key Financial Metrics
The filing focuses exclusively on revenue breakdowns. No data regarding profit, cash flow, margins, debt, or liquidity is provided in this document.
Annual Revenue (in thousands)
| Category | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Foundational | $1,028,540 | $964,100 | $926,253 | $862,375 |
| Therapeutic | $487,366 | $392,414 | $331,113 | $288,606 |
| Total Revenue | $1,515,906 | $1,356,514 | $1,257,366 | $1,150,981 |
Quarterly Revenue Comparison (in thousands)
| Quarter | 2025 Total | 2024 Total | 2025 Foundational | 2025 Therapeutic |
|---|---|---|---|---|
| Q1 (Mar 31) | $355,351 | $323,508 | $240,382 | $114,969 |
| Q2 (Jun 30) | $382,462 | $338,003 | $262,382 | $120,080 |
| Q3 (Sep 30) | $384,157 | $339,845 | $260,906 | $123,251 |
| Q4 (Dec 31) | $393,936 | $355,158 | $264,870 | $129,066 |
Material Changes
- Revenue Growth: Total revenue increased from $1.36 billion in 2024 to $1.52 billion in 2025, representing a year-over-year increase of approximately 11.8%.
- Category Performance: Both Foundational and Therapeutic categories showed growth in 2025. Foundational revenue grew by $64.4 million, while Therapeutic revenue grew by $94.9 million compared to 2024.
- Product Platform Shifts: Within the Therapeutic category, Cardiac Therapies saw significant growth, rising from $49.4 million in 2024 to $93.4 million in 2025. Oncology and Vascular Intervention also showed consistent growth over the four-year period.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future outlook, or specific risk factors. It explicitly states that the revenue information disaggregated by product platform is provided for supplemental detail and will not be reported on a recurring basis in future periods. The information is furnished under Regulation FD and is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the impact of the new "Foundational" and "Therapeutic" categorization on future quarterly reporting consistency.
- Confirm the drivers behind the significant 89% increase in Cardiac Therapies revenue from 2024 to 2025.
- Review the full 2025 Annual Report (10-K) for corresponding profit margins, cash flow, and debt metrics, as this 8-K contains revenue data only.
- Assess whether the "Other" category in Foundational revenue (which declined from $10.9M in 2024 to $8.2M in 2025) indicates a strategic shift or market contraction.